Peg-interferon Lambda Single Dose Treatment for COVID-19: A Call to Avoid another Hydroxychloroquine Fiasco.

Abstract

In this perspective, I counter-argue a claim that was recently made that a single dose of Peg-interferon lambda can significantly lower incidence of COVID-19 hospitalizations or emergency department visits. Some major flaws in a recently published article that suggested this benefit are discussed while asking the global authorities to learn from the prior mistakes and to be of utmost caution when considering its final decision regarding adoption of a single dose of Peg-interferon lambda to manage COVID-19. It has been declined to be published by the respective NEJM that published the fraudulent claim without any comment and it's reasonable that many journals might be hesitant to allow a peer review. However, no matter my argument could seem harsh, the loss of millions of lives due to corrupted American journals and health care authorities that allowed failure pharmacotherapeutics to manage COVID-19 patients in return of billions of dollars profits is much harsher and I'll not be surprised if this preprint follows numerous previous ones that I was tired and eventually gave up and stopped seeking to find a peer review opportunity.